Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Mesothelioma: HELP
Articles by Aliya Husain
Based on 4 articles published since 2010
(Why 4 articles?)
||||

Between 2010 and 2020, Aliya Husain wrote the following 4 articles about Mesothelioma.
 
+ Citations + Abstracts
1 Review The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. 2017

Marchevsky, Alberto M / LeStang, Nolwenn / Hiroshima, Kenzo / Pelosi, Giuseppe / Attanoos, Richard / Churg, Andrew / Chirieac, Lucian / Dacic, Sanja / Husain, Aliya / Khoor, Andras / Klebe, Sonja / Lantuejoul, Silvie / Roggli, Victor / Vignaud, Jean-Michel / Weynard, Birgit / Sauter, Jennifer / Henderson, Douglas / Nabeshima, Kasuzi / Galateau-Salle, Francoise. ·Department of Pathology Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address: Alberto.Marchevsky@cshs.org. · Department of Pathology, MESOPATH-MESOBANK, Centre León Bérard, Lyon, France. · Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan. · Interhospital Pathology Division, Università degli Studi di Milano and IRCCS MultiMedica Group, Milan, Italy. · Department of Pathology University of Wales and Cardiff University, Cardiff, U.K. · Department of Pathology, University of British Columbia, Vancouver, BC. · Department of Pathology, Brigham and Women's Hospital, Boston, MA. · Department of Pathology UPMC-PUH, Pittsburgh, PA. · Department of Pathology, Chicago University, Chicago, IL. · Department of Pathology, Mayo Clinic, Jacksonville, FL. · SA Pathology at Flinders Medical Cemtre, Bedord Park, SA. · Department of Pathology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France. · Department of Pathology Duke University, Durham, NC. · Department of Pathology, CHU de Nancy, Nancy, France. · University Hospital Leuven, Leuven, Belgium. · Department of Pathology Sloan Kettering Memorial Cancer Center, New York, NY. · Department of Pathology Fukuoka University Hospital, Fukuoka, Japan. ·Hum Pathol · Pubmed #28782639.

ABSTRACT: Immunohistochemistry is used to distinguish sarcomatoid malignant mesotheliomas (SMM) from spindle cell and pleomorphic carcinomas (SPC) but there are no guidelines on how to interpret cases that show overlapping or equivocal immunohistochemical findings. A systematic literature review of the immunophenotype of these lesions was performed and the experience with 587 SMM and 46 SPC at MESOPATH was collected. Data were analyzed with Comprehensive Meta-Analysis 2.0 software (Biostat, Englewood, NJ). There were insufficient data to evaluate the differential diagnosis between SPC and localized SMM or peritoneal SMM. Meta-analysis showed considerable overlap in the immunophenotype of these neoplasms and significant data heterogeneity amongst many of the results. Survival data from MESOPATH patients showed no significant differences in overall survival between SMM and SPC patients. Best available evidence was used to formulate several evidence-based guidelines for the differential diagnosis between pleural SMM and SPC. These guidelines emphasize the need to correlate the histopathological findings with clinical and imaging information. Diffuse SMM can be diagnosed with certainty in the presence of malignant spindle cell pleural lesions showing immunoreactivity for cytokeratin and mesothelial markers and negative staining for epithelial markers. Criteria for the interpretation of various other combinations of immunoreactivity for cytokeratin and mesothelial and/or epithelial markers are proposed. Localized sarcomatoid mesotheliomas can only be diagnosed in the presence of spindle cell malignancies that exhibit immunoreactivity for cytokeratin and mesothelial markers and negative immunoreactivity for epithelial lesions, in patients that show no multifocal or diffuse pleural spread and no evidence for extrapleural lesions.

2 Article EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. 2020

Nicholson, Andrew G / Sauter, Jennifer L / Nowak, Anna K / Kindler, Hedy L / Gill, Ritu R / Remy-Jardin, Martine / Armato, Samuel G / Fernandez-Cuesta, Lynnette / Bueno, Raphael / Alcala, Nicolas / Foll, Matthieu / Pass, Harvey / Attanoos, Richard / Baas, Paul / Beasley, Mary Beth / Brcic, Luka / Butnor, Kelly J / Chirieac, Lucian R / Churg, Andrew / Courtiol, Pierre / Dacic, Sanja / De Perrot, Marc / Frauenfelder, Thomas / Gibbs, Allen / Hirsch, Fred R / Hiroshima, Kenzo / Husain, Aliya / Klebe, Sonja / Lantuejoul, Sylvie / Moreira, Andre / Opitz, Isabelle / Perol, Maurice / Roden, Anja / Roggli, Victor / Scherpereel, Arnaud / Tirode, Frank / Tazelaar, Henry / Travis, William D / Tsao, Ming-Sound / van Schil, Paul / Vignaud, Jean Michel / Weynand, Birgit / Lang-Lazdunski, Loic / Cree, Ian / Rusch, Valerie W / Girard, Nicolas / Galateau-Salle, Francoise. ·Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom. Electronic address: a.nicholson@rbht.nhs.uk. · Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. · Medical School, University of Western Australia, Perth, Australia. · Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, Illinois. · Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massacheusetts. · Department of Thoracic Imaging, Hospital Calmette, University Centre of Lille, France. · Department of Radiology, The University of Chicago, Chicago, Illinois. · Section of Genetics, International Agency for Research on Cancer (IARC/WHO), Lyon, France. · Division of Thoracic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. · Cardiothoracic Surgery, NYU Langone Health, New York, New York. · Department of Cellular Pathology, University Hospital of Wales, School of Medicine, Cardiff University, United Kingdom. · Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Department of Pathology, Mount Sinai Medical Center, New York, New York. · Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria. · Department of Pathology & Laboratory Medicine, The University of Vermont Medical Center, Burlington, Vermont. · Department of Pathology, Brigham and Women's Hospital, Boston, Massacheusetts. · Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada. · Owkin Inc., Paris, France. · Department of Pathology University of Pittsburgh Medical Center, Pennsylvania. · Division of Thoracic Surgery, Princess Margaret Cancer Centre, Toronto, Canada. · Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland. · Department of Cellular Pathology, Cardiff and Vale UHB, Cardiff, Wales, United Kingdom. · Center for Thoracic Oncology, Mount Sinai Health System, New York, New York. · Department of Pathology, Tokyo Women's Medical University, Yachiyo Medical Center, Tokyo, Japan. · Department of Pathology, University of Chicago, Chicago, Illinois. · Department of Anatomical Pathology, SA Pathology and Flinders University, Adelaide, Australia. · Department of Biopathology and of Translational Research and Innovation, CNR MESOPATH, Centre Leon Berard Lyon, and Grenoble Alpes University, France. · Department of Pathology, New York University Langone Health, New York, New York. · Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland. · Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France. · Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. · Department of Pathology, Duke University Medical Center, Durham, North Carolina. · Pulmonary and Thoracic Oncology Department, University Lille, CHU Lille, France. · Université Lyon, Centre Léon Bérard, Cancer Research Center of Lyon, France. · Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona. · Department of Pathology, University Health Network, Princess Margaret Cancer Centre, Toronto, Canada. · Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Belgium. · CHU Nancy, Université Lorraine, Nancy, France. · Department of Pathology, UZ Leuven, Leuven, Belgium. · Cromwell Hospital, London, United Kingdom. · International Agency for Research on Cancer (IARC), Lyon, France. · Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. · Institut Curie, Institut du Thorax Curie Montsouris, Paris, France. · MESOPATH Centre Leon Berard, Lyon, France. ·J Thorac Oncol · Pubmed #31546041.

ABSTRACT: INTRODUCTION: Molecular and immunologic breakthroughs are transforming the management of thoracic cancer, although advances have not been as marked for malignant pleural mesothelioma where pathologic diagnosis has been essentially limited to three histologic subtypes. METHODS: A multidisciplinary group (pathologists, molecular biologists, surgeons, radiologists, and oncologists), sponsored by European Network for Rare Adult Solid Cancers/International Association for the Study of Lung Cancer, met in 2018 to critically review the current classification. RESULTS: Recommendations include: (1) classification should be updated to include architectural patterns and stromal and cytologic features that refine prognostication; (2) subject to data accrual, malignant mesothelioma in situ could be an additional category; (3) grading of epithelioid malignant pleural mesotheliomas should be routinely undertaken; (4) favorable/unfavorable histologic characteristics should be routinely reported; (5) clinically relevant molecular data (programmed death ligand 1, BRCA 1 associated protein 1 [BAP1], and cyclin dependent kinase inhibitor 2A) should be incorporated into reports, if undertaken; (6) other molecular data should be accrued as part of future trials; (7) resection specimens (i.e., extended pleurectomy/decortication and extrapleural pneumonectomy) should be pathologically staged with smaller specimens being clinically staged; (8) ideally, at least three separate areas should be sampled from the pleural cavity, including areas of interest identified on pre-surgical imaging; (9) image-acquisition protocols/imaging terminology should be standardized to aid research/refine clinical staging; (10) multidisciplinary tumor boards should include pathologists to ensure appropriate treatment options are considered; (11) all histologic subtypes should be considered potential candidates for chemotherapy; (12) patients with sarcomatoid or biphasic mesothelioma should not be excluded from first-line clinical trials unless there is a compelling reason; (13) tumor subtyping should be further assessed in relation to duration of response to immunotherapy; and (14) systematic screening of all patients for germline mutations is not recommended, in the absence of a family history suspicious for BAP1 syndrome. CONCLUSIONS: These multidisciplinary recommendations for pathology classification and application will allow more informative pathologic reporting and potential risk stratification, to support clinical practice, research investigation and clinical trials.

3 Article Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. 2017

Kiyotani, Kazuma / Park, Jae-Hyun / Inoue, Hiroyuki / Husain, Aliya / Olugbile, Sope / Zewde, Makda / Nakamura, Yusuke / Vigneswaran, Wickii T. ·Department of Medicine, The University of Chicago , Chicago, IL, USA. · Department of Pathology, The University of Chicago , Chicago, IL, USA. · Department of Medicine, The University of Chicago, Chicago, IL, USA; Department of Surgery, The University of Chicago, Chicago, IL, USA. · Department of Surgery, The University of Chicago, Chicago, IL, USA; Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL, USA. ·Oncoimmunology · Pubmed #28344893.

ABSTRACT: To investigate the link between the genomic landscape of cancer cells and immune microenvironment in tumor tissues, we characterized somatic mutations and tumor-infiltrating lymphocytes (TILs) in malignant pleural mesothelioma (MPM), including mutation/neoantigen load, spatial heterogeneity of somatic mutations of cancer cells and TILs (T-cell receptor β (TCRβ) repertoire), and expression profiles of immune-related genes using specimens of three different tumor sites (anterior, posterior, and diaphragm) obtained from six MPM patients. Integrated analysis identified the distinct patterns of somatic mutations and the immune microenvironment signatures both intratumorally and interindividually. MPM cases showed intratumoral heterogeneity in somatic mutations with unique TCRβ clonotypes of TILs that were restricted to each tumor site, suggesting the presence of a neoantigen-related immune response. Correlation analyses showed that higher neoantigen load was significantly correlated with stronger clonal expansion of TILs (

4 Article Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. 2016

Lennon, Frances E / Cianci, Gianguido C / Kanteti, Rajani / Riehm, Jacob J / Arif, Qudsia / Poroyko, Valeriy A / Lupovitch, Eitan / Vigneswaran, Wickii / Husain, Aliya / Chen, Phetcharat / Liao, James K / Sattler, Martin / Kindler, Hedy L / Salgia, Ravi. ·Department of Medicine, Section of Hematology/Oncology and the Comprehensive Cancer Center, University of Chicago, Chicago, IL, 60637, USA. · Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. · Department of Pathology, University of Chicago, Chicago, IL, 60637, USA. · Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA. · University of Maryland, College Park, MD, 20742, USA. · Department of Surgery, University of Chicago, Chicago, IL, 60637, USA. · Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL, 60637, USA. · Department of Medicine, Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. ·Sci Rep · Pubmed #27080907.

ABSTRACT: Malignant mesothelioma (MM), is an intractable disease with limited therapeutic options and grim survival rates. Altered metabolic and mitochondrial functions are hallmarks of MM and most other cancers. Mitochondria exist as a dynamic network, playing a central role in cellular metabolism. MM cell lines display a spectrum of altered mitochondrial morphologies and function compared to control mesothelial cells. Fractal dimension and lacunarity measurements are a sensitive and objective method to quantify mitochondrial morphology and most importantly are a promising predictor of response to mitochondrial inhibition. Control cells have high fractal dimension and low lacunarity and are relatively insensitive to mitochondrial inhibition. MM cells exhibit a spectrum of sensitivities to mitochondrial inhibitors. Low mitochondrial fractal dimension and high lacunarity correlates with increased sensitivity to the mitochondrial inhibitor metformin. Lacunarity also correlates with sensitivity to Mdivi-1, a mitochondrial fission inhibitor. MM and control cells have similar sensitivities to cisplatin, a chemotherapeutic agent used in the treatment of MM. Neither oxidative phosphorylation nor glycolytic activity, correlated with sensitivity to either metformin or mdivi-1. Our results suggest that mitochondrial inhibition may be an effective and selective therapeutic strategy in mesothelioma, and identifies mitochondrial morphology as a possible predictor of response to targeted mitochondrial inhibition.